Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scans reveal hidden damage in COVID Long-Haulers

NCT ID NCT05920616

Knowledge-focused Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study used advanced MRI and CT scans to look for lasting damage in the brain, heart, lungs, and liver of 206 people who had COVID-19. Researchers compared those who were hospitalized with those who were not, to understand how the virus affects organs over time. The goal is to help prevent, detect, and manage long-term complications from COVID-19.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better detect and manage long-term organ damage from COVID-19.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove that any intervention works, and results may not apply to all COVID-19 survivors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

206 people

The number who actually took part.

Started

Oct 2020

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: 18+ * Diagnosed with COVID-19 at any point starting March 2020. * Subgroup A: hospitalized due to COVID-19 infection * Subgroup B: non-hospitalized Exclusion Criteria: * Known allergy to either gadolinium or iodine based contrast agents * Glomerular Filtration Rate (GFR) \<45 mL/min (using the Cockcroft-Gault formula) * Pregnancy * Internal electrical devices, such as cochlear implant, spinal cord stimulator, pacemaker, or defibrillator * Atrial fibrillation, uncontrolled tachyarrhythmia or advanced atrioventricular block (2nd or 3rd degree) at time of imaging * Evidence of severe symptomatic heart failure (NYHA Class III or IV) at the time of imaging * Other acute illness * Ongoing mechanical ventilation related to hospitalization for COVID-19 related illness * Presence of any other history or condition that the investigator feels would be problematic * Weight exceeding 300 lbs (MRI table weight restrictions) * Severe claustrophobia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID -19 COVID long-haul

Contacts and locations

Locations

  • Johns Hopkins School of Medicine

    Baltimore, Maryland, 21205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.